TISSUE ORGANOIDS

• US 20200131482A1
• Filed: 12/08/2017
• Published: 04/30/2020
• Est. Priority Date: 12/09/2016
• Status: Abandoned Application

• Current Assignee: University of Chicago
• Original Assignee: University of Chicago
• Inventors: WU, Xiaoyang, XU, Ming, YUE, Jiping
• Application Number:
  US16/467,754
• Publication Number:
  US 20200131482A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: C07K 14/755 Factors VIII , e.g. factor VIII C (AHF), factor VIII Ag (VWF)
• CPC Class Codes: C12N 2502/99 genetically modified cells
• CPC Class Codes: C12N 5/0697 Artificial constructs associating cells of different lineages, e.g. tissue equivalents blood vessels C12N5/0691
• CPC Class Codes: C12N 5/0698 Skin equivalents
• CPC Class Codes: C12Y 403/01024 Phenylalanine ammonia-lyase (4.3.1.24)
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism

Abstract

Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual'"'"'s health.

Claims

1. A physiologically-tailored tissue organoid, comprising:

a plurality of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent,

wherein when the therapeutic agent is administered to an individual in need thereof, the therapeutic agent improves the individual'"'"'s health.

2. The physiologically-tailored tissue organoid of claim 1, wherein the tissue organoid comprises a stratified skin graft grown from cells taken from an individual.

3. The physiologically-tailored tissue organoid of claim 1, wherein the tissue organoid comprises a cultured skin graft grown from embryonic stem cells, human induced pluripotent stem cells, epidermal stem cells, or keratinocytes.

10. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent comprises an enzyme, a protein, a clotting factor, a vitamin, a peptide, a lipid, a toxin, or a combination thereof.

11. The physiologically-tailored tissue organoid of claim 10, wherein expression of the therapeutic agent is inducible by an inducer.

50. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent comprises phenylalanine ammonia lyase (PAL).

51. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent improves the individual'"'"'s health by treating phenylketonuria (PKU).

52. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent comprises Factor VIII or Factor IX.

53. The physiologically-tailored tissue organoid of claim 52, wherein the therapeutic agent is conjugated with albumin.

54. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent improves the individual'"'"'s health by treating hemophilia.

55. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent comprises hBChE.

56. The physiologically-tailored tissue organoid of claim 55, wherein the therapeutic agent improves the individual'"'"'s health by treating cocaine addiction.

57. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent comprises one or more of DkTx, VaTx, glucagon-like peptide 1 (GLP-1), a GLP-1 analog, a modified GLP-1 (mGLP1), and a mGLP1 analog.

58. The physiologically-tailored tissue organoid of claim 57, wherein the therapeutic agent is inducible by alcohol consumption by the individual.

59. The physiologically-tailored tissue organoid of claim 58, wherein the therapeutic agent improves the individual'"'"'s health by treating alcoholism.

60. The physiologically-tailored tissue organoid of claim 1, wherein the therapeutic agent improves the individual'"'"'s health by treating nicotine or amphetamine addiction.

4-9. -9. (canceled)

12-28. -28. (canceled)

29. A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:

contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agents.

30. The method of claim 29, wherein the tissue organoid is biointegrated into the individual by grafting or surgical implantation.

31. The method of claim 29, wherein the disease or disorder is PKU or hemophilia, and

wherein the addiction is one or more of cocaine addiction, alcoholism, nicotine addiction, or amphetamine addiction.

32-49. -49. (canceled)

61. A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:

contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent, wherein expression of the therapeutic agent is inducible by an inducer; and

administering an inducer to the individual to induce expression of the therapeutic agent.